Innovative approaches to measuring outcomes and providing feedback: The Opioid Agonist Therapy Effectiveness (OpiATE) initiative

Journal of Maintenance in the Addictions

Volumn 3, Issue 1, 2006, Pages 13-32

  Willenbring, Mark L ^a,b,c   Postier, Andrea C ^d   Kenny, Marie E ^e   Hagedorn, Hildi J ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d GILLETTE CHILDREN'S SPECIALTY HEALTHCARE   (United States)

^e VA MEDICAL CENTER   (United States)

Author keywords

Health care evaluation mechanisms; Opiate addiction and opiate dependence; Outcome process and assessment (health care); Treatment outcomes

Indexed keywords

EID: 33746602241     PISSN: 10911332     EISSN: 15407624     Source Type: Journal    
DOI: 10.1300/J126v03n01_03     Document Type: Article

References (28)

1. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag; 1991.
2. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opioid dependence: a multicenter, randomized clinical trial. Addiction 1998;93(4):475-86.
3. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior, and criminality: a meta-analysis. Addiction 1998;93:515-32.
4. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA 1993;269(15):1953-9.
5. Newman RG, Whitehill WB. Double-blind comparisons of methadone and placebo maintenance treatments of narcotic addicts. Lancet North Am Ed 1979;8141:485-8.
6. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283(10):1303-10.
7. Zaric GS, Barnett P, Brandeau M. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000;90:1100-11.
8. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA 1992;267(2):253-28.
9. Hamilton EG, Humphreys K. Outpatient methadone services in Department of Veterans Affairs. Palo Alto, CA: VA Program Evaluation and Resource Center; 1996.
10. Hartel DM, Schoenbaum EE, Selwyn PA, et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health 1995;85(1):83-8.
11. Caplehorn JR, Dalton MS, Cluff MC, Petrenas A. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1989;89:203-7.
12. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998;88(1):34-9.
13. Eissenberg T, Bigelow GE, Strain EC, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA 1997;22 (24):1945-51.
14. McGlothlin WH, Anglin D. Long-term follow-up of clients of high-dose and low-dose programs. Arch Gen Psychiatry 1981;38:1055-63.
15. del Rio M, Mino A, Perneger TV. Predictors of patient retention in a newly established methadone maintenance treatment program. Addiction 1997;92(10):1353-60.
16. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998;52(2):167-71.
17. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatment for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry 1976;33:709-20.
18. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281(11):1000-5.
19. Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154:195-9.
20. NIH dosing consensus statement. Effective medical treatment of opiate addiction. NIH Consensus Statement Online 1997 Nov17-19;15(6):1-38. Available from: URL: http://www.nichd.nih.gov/publications/pubs/pku/sub3.htm
21. Kraft MK, Rothbard AB, Hadley TR, McLellan AT, Asch DA. Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatry 1997;154(9):1214-9.
22. Broome KM, Simpson DD, Joe GW. Patient and program attributes related to treatment process indicators in DATOS. Drug Alcohol Depend 1999;57:127-35.
23. Hser Y, Grella CE, Hsieh S, Anglin MD, Brown BS. Prior treatment experience related to process and outcomes in DATOS. Drug Alcohol Depend 1999;57:137-50.
24. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend 1999;57:113-25.
25. Magura S, Nwakeze PC, Demsky SY. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998;93(1):51-60.
26. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med, 2001;68(1):62-74.
27. Caplehorn JRM, McNeil DR, Kleinbaum DG. Clinic policy and retention in methadone maintenance. Int J Addict 1993;28(1):73-89.
28. Stitzer M, Bigelow GE, Liebson I. Reducing drug use among methadone maintenance clients: contingent reinforcement for morphine-free urines. Addict Behav 1980;5:333-40.